REHOVOT, Israel, February 28 /PRNewswire/ -- D-Pharm Ltd., a privately held biopharmaceutical company, announced today that it will present at the forthcoming BioSquare 2006 Conference. The presentation will be made by Dr. Alex Kozak, President and Chief Executive Officer, on March 9th at 5.00 pm at the International Conference Center in Geneva.
D-Pharm is an integrated drug discovery and drug development organisation with a rich and innovative pipeline of drug-candidates generated from its technology platform: Regulated Activation of Prodrugs (D-RAP(TM)); and its drug discovery platforms Membrane Active Chelators (MAC) and LipidoMimetix, bioactive lipids. D-Pharm focuses primarily on discovery, design and development of drugs for treatment of CNS disorders and cancer.
D-Pharm has two products in advanced Phase II, four early-stage Phase II programs and several products which can enter clinical development within 12 to 18 months. D-Pharm is currently seeking licensing or strategic partner(s) for continued development of DP-VPA, a Phase II candidate for epilepsy, with therapeutic potential in migraine prophylaxis and bipolar disorder; DP-109, a preclinical candidate for Alzheimer’s disease, which reduces amyloid plaque load and improves cognition and behaviour in transgenic mouse models for Alzheimer’s disease; as well as for earlier R&D stage cancer products. D-Pharm intends to complete the on-going Phase IIb study of DP-b99 in acute stroke patients before partnering for further development and commercialisation.
For further information, please contact: Tami Horovitz D-Pharm Ltd. Tel: +972-8-9385100 Fax: +972-8-9300795 Email: thorovitz@dpharm.com
D-Pharm Ltd
CONTACT: Tami Horovitz, D-Pharm Ltd., Tel: +972-8-9385100, Fax:+972-8-9300795, Email: thorovitz@dpharm.com
